Proprietary AI analyst is now available

Vazyme Biotech Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vazyme Biotech and similar public comparables like Suzhou Sepax Technologies, GemPharmatech, Absci, VCANBIO and more.

Vazyme Biotech Overview

About Vazyme Biotech

Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.


Founded

2012

HQ

China

Employees

N/A

Website

vazyme.com

Financials (LTM)

Revenue: $218M
EBITDA: $35M

EV

$915M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vazyme Biotech Financials

Vazyme Biotech reported last 12-month revenue of $218M and EBITDA of $35M.

In the same LTM period, Vazyme Biotech generated $152M in gross profit, $35M in EBITDA, and $6M in net income.

Revenue (LTM)


Vazyme Biotech P&L

In the most recent fiscal year, Vazyme Biotech reported revenue of $204M and EBITDA of $23M.

Vazyme Biotech is unprofitable as of last fiscal year, with gross margin of 70%, EBITDA margin of 11%, and net margin of (1%).

See analyst estimates for Vazyme Biotech
LTMLast FY202320242025202620272028
Revenue$218M$204M$190M$204M$204M
Gross Profit$152M$142M$135M$142M$142M
Gross Margin70%70%71%70%70%
EBITDA$35M$23M$11M$18M$20M
EBITDA Margin16%11%6%9%10%
EBIT Margin3%(3%)(3%)(4%)(3%)
Net Profit$6M($2M)($10M)($3M)($2M)
Net Margin3%(1%)(6%)(1%)(1%)

Financial data powered by Morningstar, Inc.

Vazyme Biotech Stock Performance

Vazyme Biotech has current market cap of $1B, and enterprise value of $915M.

Market Cap Evolution


Vazyme Biotech's stock price is $2.32.

Vazyme Biotech share price decreased by 17.7% in the last 30 days, and by 29.3% in the last year.

See more trading valuation data for Vazyme Biotech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$915M$1B0.0%-17.7%-19.0%-29.3%$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vazyme Biotech Valuation Multiples

Vazyme Biotech trades at 4.2x EV/Revenue multiple, and 25.9x EV/EBITDA.

See NTM and 2027E valuation multiples for Vazyme Biotech

EV / Revenue (LTM)


Vazyme Biotech Financial Valuation Multiples

As of June 22, 2026, Vazyme Biotech has market cap of $1B and EV of $915M.

Vazyme Biotech has a P/E ratio of 212.9x.

LTMLast FY202320242025202620272028
EV/Revenue4.2x4.5x4.8x4.5x4.5x
EV/EBITDA25.9x40.0x80.7x51.0x45.4x
EV/EBIT166.1x(173.0x)(161.8x)(111.5x)(173.0x)
EV/Gross Profit6.0x6.5x6.8x6.4x6.5x
P/E212.9xn/m(114.5x)n/mn/m
EV/FCF-33.3x(77.5x)(73.2x)33.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vazyme Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vazyme Biotech Margins & Growth Rates

Vazyme Biotech grew revenue by 16% and EBITDA by 116% in the last fiscal year.

In the most recent fiscal year, Vazyme Biotech reported gross margin of 70%, EBITDA margin of 11%, and net margin of (1%).

See estimated margins and future growth rates for Vazyme Biotech

Vazyme Biotech Margins

Last FY202420252026202720282029
Gross Margin70%70%70%70%
EBITDA Margin11%9%10%21%
EBIT Margin(3%)(4%)(3%)8%
Net Margin(1%)(1%)(1%)6%
FCF Margin13%(6%)13%-

Vazyme Biotech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth16%7%(0%)16%
Gross Profit Growth17%5%(1%)17%
EBITDA Growth116%58%12%144%
EBIT Growth(442%)45%(36%)(442%)
Net Profit Growth(697%)(75%)(8%)(697%)
FCF Growth-6%(320%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Vazyme Biotech Operational KPIs

Vazyme Biotech's Rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vazyme Biotech's Rule of X is 60% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Vazyme Biotech
LTMLast FY202320242025202620272028
Rule of 4033%37%---
Bessemer Rule of X59%60%---
S&M Expenses to Revenue35%37%14%14%12%
G&A Expenses to Revenue15%15%4%4%3%
R&D Expenses to Revenue19%20%26%22%20%
Opex to Revenue-72%74%74%72%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Vazyme Biotech Competitors

Vazyme Biotech competitors include Suzhou Sepax Technologies, GemPharmatech, Absci, VCANBIO, Eckert & Ziegler, Personalis, Azenta, OPKO Health, CareDx and Oxford Nanopore Technologies.

Most Vazyme Biotech public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Suzhou Sepax Technologies19.4x17.1x46.9x-
GemPharmatech8.8x8.1x27.1x24.3x
Absci369.3x250.5x(10.0x)(9.2x)
VCANBIO4.8x-20.6x-
Eckert & Ziegler2.8x2.8x9.5x9.5x
Personalis13.1x12.3x(12.8x)(10.0x)
Azenta1.3x1.3x11.3x12.1x
OPKO Health1.9x2.0x(27.3x)(8.6x)

This data is available for Pro users. Sign up to see all Vazyme Biotech competitors and their valuation data.

Start Free Trial

Vazyme Biotech VC Funding History

Before going public, Vazyme Biotech raised $164M in total equity funding, across 3 rounds.


Vazyme Biotech Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-20Series CSherpa Healthcare Partners; China Life Private Equity Investment$84M--
May-20Series CChina Life Insurance$78M-Nanjing Vazyme Biotech Co., Ltd., founded in 2012, develops enzymes and antibodies for clinical diagnosis, molecular diagnostics, and high-throughput sequencing applications. The company gained prominence with regulatory approval for its Covid-19 detection kit around the time of its Series C round. Vazyme has raised multiple funding rounds prior, including angel funding in 2013 from Danen Capital, pre-Series A and Series A in 2016 from investors like GF Xinde Investment and Share Capital, and Series B in 2019 led by Huatai Group's healthcare fund with Everest Venture Capital. On or about May 8, 2020, Vazyme closed a RMB550 million ($78 million) Series C round led by China Life Insurance's healthcare fund, with participation from Sherpa Capital. This funding supports commercialization of raw materials and reagents, expansion of proprietary production for research organizations reliant on imports, and scaling Covid-19 kit production approved for mass production and export. For fiscal year 2020, Vazyme reported 1.56 billion CNY in sales from Diagnostic Kits/Equipment, with total China sales at 1.35 billion CNY and overseas at 213 million CNY. Subsequent years showed growth in Research and Experimental Development (1.43 billion CNY in 2021) and Pharmaceutical Manufacturing (439 million CNY in 2021), alongside total sales increases peaking at 3.34 billion CNY in China in 2022. The company later went public, with shareholder data including Lin Cao holding 52.92% valued at 646 million CNY and China Life Private Equity listed among investors.
Aug-18Series BEverest Venture Capital$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vazyme Biotech

When was Vazyme Biotech founded?Vazyme Biotech was founded in 2012.
Where is Vazyme Biotech headquartered?Vazyme Biotech is headquartered in China.
Is Vazyme Biotech publicly listed?Yes, Vazyme Biotech is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Vazyme Biotech?Vazyme Biotech trades under 688105 ticker.
When did Vazyme Biotech go public?Vazyme Biotech went public in 2021.
Who are competitors of Vazyme Biotech?Vazyme Biotech main competitors include Suzhou Sepax Technologies, GemPharmatech, Absci, VCANBIO, Eckert & Ziegler, Personalis, Azenta, OPKO Health, CareDx, Oxford Nanopore Technologies.
What is the current market cap of Vazyme Biotech?Vazyme Biotech's current market cap is $1B.
What is the current revenue of Vazyme Biotech?Vazyme Biotech's last 12 months revenue is $218M.
What is the current revenue growth of Vazyme Biotech?Vazyme Biotech revenue growth (NTM/LTM) is 17%.
What is the current EV/Revenue multiple of Vazyme Biotech?Current revenue multiple of Vazyme Biotech is 4.2x.
What is the current EBITDA of Vazyme Biotech?Vazyme Biotech's last 12 months EBITDA is $35M.
What is Vazyme Biotech's EBITDA margin?Vazyme Biotech's last 12 months EBITDA margin is 16%.
What is the current EV/EBITDA multiple of Vazyme Biotech?Current EBITDA multiple of Vazyme Biotech is 25.9x.
How many companies Vazyme Biotech has acquired to date?Vazyme Biotech hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Vazyme Biotech has invested to date?Vazyme Biotech hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Vazyme Biotech

Lists including Vazyme Biotech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial